Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C. , April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced

Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide

New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen)

Labcorp to Announce First Quarter Financial Results on April 29, 2025

BURLINGTON, N.C. , March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc.  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025 .

Considerations for the accelerated acceptance of new approach methodologies (NAMs) and in-vitro alternatives for product testing and development

Biopharma, chemical and other companies seeking to develop new products or compounds face the challenge of navigating complex animal research regulations and routine ethical considerations. Many are opting for innovations in conducting research that replaces or reduces animal use while still meeting regulatory requirements and ensuring product safety

Cell and Gene Therapy Answers: Understanding gene editing and its possible applications

Your source for answers to the complex challenges of cell and gene therapy development.Gene editing offers new possibilities for treating genetic diseases, enhancing immunotherapies, strengthening immune systems and more. To learn more about this cutting-edge technology, including key considerations, emerging opportunities and its potential to transform healthcare, we spoke to NingChun Liu, enterprise director for cell and gene therapy at Labcorp. 

Strategies to address above-the-limit-of-quantitation results when samples are depleted

Evaluating concentration-dependent blood partitioning and establishing best practices for assessing whole blood stability

Cell Therapies in the Treatment of Autoimmune Diseases

Cell therapies offer new hope for treating autoimmune diseases, but unique challenges persist. Discover how cutting-edge gene editing techniques are addressing longstanding issues from self-antigen recognition to inflammatory microenvironments. 

The Cardiorenal Connection: Highlighting Cardiovascular Risk in Chronic Kidney Disease

Cinven completes sale of minority stake in SYNLAB to strategic investor Labcorp

March 24, 2025 -- International private equity firm Cinven has completed its previously announced sale of an indirect minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, to strategic investor Labcorp. Labcorp is a global leader of innovative and